Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Drosfemine
- Development stage
- Phase 4
- Lead developer
- DermaPharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Drosfemine is a combined oral contraceptive (COC) containing the synthetic estrogen ethinylestradiol and the progestin drospirenone. Developed by Mibe Arzneimittel, it is primarily indicated for the prevention of pregnancy (birth control) and may also be used to manage moderate acne vulgaris and symptoms of premenstrual dysphoric disorder (PMDD). Ethinylestradiol acts as an estrogen receptor agonist, while drospirenone acts as a progesterone receptor agonist to inhibit ovulation, thicken cervical mucus, and alter the endometrium to prevent implantation. Additionally, drospirenone exhibits antimineralocorticoid and antiandrogenic properties, which help reduce water retention and acne.
- Brand names
- DrosfemineDrosfemine ForteDrosfemine Mini
- Other names
- drospirenone + ethinylestradioldrospirenone/ethinylestradiolethinylestradiol + drospirenoneethinylestradiol/drospirenone
02
Targets
AR (Adrenergic receptors)MR (Mineralocorticoid receptor)PR (Progesterone receptor)ER (Estrogen receptor)
Beyond the preview
Go deeper on Drosfemine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Drosfemine.